Loading data for AMLX — first visit, this takes a few seconds.

알림

Amylyx Pharmaceuticals In... (AMLX)

NasdaqGS: AMLX · 실시간 가격 · USD

38.13

+3.02 (8.60%)

종가 기준: Aug 18, 2026, 3:59 PM

8.60% (1D)

매수호가	n/a
시가총액	4.25B
매출 (ttm)	n/a
순이익 (ttm)	-152.09M
베타	-0.20
EPS (ttm)	-1.41
P/E (ttm)	n/a
선행 P/E	-32.67
P/B (ttm)	17.75
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

매도호가	n/a
거래량	4,503,259
평균 거래량 (20일)	2,043,522
시가	36.11
전일 종가	35.11
일중 범위	35.32 - 38.83
52주 범위	7.82 - 38.83
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

AMLX 소개

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also devel...

섹터 Healthcare

IPO 일자 Jan 7, 2022

직원 수 136

상장 거래소 NasdaqGS

티커 AMLX

웹사이트 https://amylyx.com

전체 기업 정보

재무 실적

2025년 Amylyx Pharmaceuticals의 매출은 0로, 전년 87.37M 대비 -100% 감소했습니다. 순이익은 -144.74M로, -52.03% 감소했습니다.

재무제표

어닝 서프라이즈

Amylyx Pharmaceuticals가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.39 예상치 하회 -0.03, 및 15.22% 전년 대비 성장.

다음 실적 발표

Amylyx Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

18시간 전 · Insider Monkey

Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) soared to a new three-year high on Tuesday after its treatment candidate for post-bariatric hypoglycemia (PBH) reported strong results in phase 3 clinical stu...

18시간 전 · Motley Fool

Why Amylyx Pharmaceuticals Stock Skyrocketed Today

GLP-1 drugs aren't just for weight loss.

20시간 전 · Stocktwits

AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering

The capital raise comes as Amylyx prepares to move from clinical success toward potential commercialization, following the positive trial data for avexitide announced earlier today.

21시간 전 · Barrons.com

Micron, Coherent, SpaceX, Klarna, Amylyx, and More Stocks That Explain Today’s Market

FEATURE Stocks dropped Tuesday, dragged down by pressure on artificial-intelligence infrastructure companies and heightened tensions in the Middle East. Optical network provider Coherent sank 13%, ma...

21시간 전 · Investor's Business Daily

A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High

Amylyx stock skyrocketed Tuesday after its GLP-1 drug reduced hypoglycemia in patients who've undergone bariatric surgery.

2 페이지 중 1